JP2019524802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524802A5 JP2019524802A5 JP2019507107A JP2019507107A JP2019524802A5 JP 2019524802 A5 JP2019524802 A5 JP 2019524802A5 JP 2019507107 A JP2019507107 A JP 2019507107A JP 2019507107 A JP2019507107 A JP 2019507107A JP 2019524802 A5 JP2019524802 A5 JP 2019524802A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- liposome
- polyglutamine
- lpa
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 239000002502 liposome Substances 0.000 claims 27
- 239000004052 folic acid antagonist Substances 0.000 claims 14
- 108010040003 polyglutamine Proteins 0.000 claims 12
- 229920000155 polyglutamine Polymers 0.000 claims 12
- 230000003432 anti-folate effect Effects 0.000 claims 11
- 229940127074 antifolate Drugs 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 8
- 229920001223 polyethylene glycol Polymers 0.000 claims 8
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 230000003647 oxidation Effects 0.000 claims 6
- 238000007254 oxidation reaction Methods 0.000 claims 6
- 229960005079 pemetrexed Drugs 0.000 claims 5
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 102000010449 Folate receptor beta Human genes 0.000 claims 4
- 108050001930 Folate receptor beta Proteins 0.000 claims 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 4
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 238000001125 extrusion Methods 0.000 claims 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229960000485 methotrexate Drugs 0.000 claims 4
- 230000001590 oxidative effect Effects 0.000 claims 4
- 229920002643 polyglutamic acid Polymers 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- 229920002498 Beta-glucan Polymers 0.000 claims 3
- 102000010451 Folate receptor alpha Human genes 0.000 claims 3
- 108050001931 Folate receptor alpha Proteins 0.000 claims 3
- 102100023119 Sperm-egg fusion protein Juno Human genes 0.000 claims 3
- 101710093389 Sperm-egg fusion protein Juno Proteins 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- -1 anionic lipid Chemical class 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 102000006815 folate receptor Human genes 0.000 claims 3
- 108020005243 folate receptor Proteins 0.000 claims 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 229920002401 polyacrylamide Polymers 0.000 claims 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229920006187 aquazol Polymers 0.000 claims 1
- 239000012861 aquazol Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 1
- 239000001639 calcium acetate Substances 0.000 claims 1
- 229960005147 calcium acetate Drugs 0.000 claims 1
- 235000011092 calcium acetate Nutrition 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 claims 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023018363A JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2024131755A JP2024160315A (ja) | 2016-08-12 | 2024-08-08 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374458P | 2016-08-12 | 2016-08-12 | |
| US62/374,458 | 2016-08-12 | ||
| US201715675695A | 2017-08-11 | 2017-08-11 | |
| US15/675,701 US20180236098A1 (en) | 2016-08-12 | 2017-08-11 | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| US15/675,695 | 2017-08-11 | ||
| US15/675,701 | 2017-08-11 | ||
| PCT/US2017/046666 WO2018031979A1 (en) | 2016-08-12 | 2017-08-12 | Alpha and gamma-d polyglutamated antifolates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018363A Division JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524802A JP2019524802A (ja) | 2019-09-05 |
| JP2019524802A5 true JP2019524802A5 (enExample) | 2020-09-24 |
| JP7227123B2 JP7227123B2 (ja) | 2023-02-21 |
Family
ID=65235618
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529465A Active JP7576816B2 (ja) | 2016-08-12 | 2017-08-12 | ポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2019507107A Active JP7227123B2 (ja) | 2016-08-12 | 2017-08-12 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2022100445A Active JP7733390B2 (ja) | 2016-08-12 | 2022-06-22 | ポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2023018363A Active JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2024131755A Pending JP2024160315A (ja) | 2016-08-12 | 2024-08-08 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2025001190A Pending JP2025072362A (ja) | 2016-08-12 | 2025-01-06 | ポリグルタミン酸化抗葉酸剤およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529465A Active JP7576816B2 (ja) | 2016-08-12 | 2017-08-12 | ポリグルタミン酸化抗葉酸剤およびその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100445A Active JP7733390B2 (ja) | 2016-08-12 | 2022-06-22 | ポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2023018363A Active JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2024131755A Pending JP2024160315A (ja) | 2016-08-12 | 2024-08-08 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2025001190A Pending JP2025072362A (ja) | 2016-08-12 | 2025-01-06 | ポリグルタミン酸化抗葉酸剤およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (11) | US11344628B2 (enExample) |
| EP (3) | EP3496757A4 (enExample) |
| JP (6) | JP7576816B2 (enExample) |
| KR (6) | KR102708208B1 (enExample) |
| CN (4) | CN121177507A (enExample) |
| AU (4) | AU2017308159B2 (enExample) |
| CA (3) | CA3033083A1 (enExample) |
| EA (1) | EA201990473A1 (enExample) |
| MX (5) | MX2019001755A (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121177507A (zh) | 2016-08-12 | 2025-12-23 | L.E.A.F.控股集团公司 | α和γ-D聚谷氨酸化抗叶酸剂及其用途 |
| WO2018031968A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| EP3749314A4 (en) * | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| EP3749321A4 (en) * | 2018-02-07 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated antifolates and uses thereof |
| JP7491572B2 (ja) * | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CN111867593A (zh) * | 2018-02-07 | 2020-10-30 | L.E.A.F.控股集团公司 | α聚谷氨酸化抗叶酸剂及其用途 |
| US12310966B2 (en) * | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157121A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| WO2019157145A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| EP3749318A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| CA3090753A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| WO2019160735A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| JP7462950B2 (ja) * | 2018-02-14 | 2024-04-08 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化メトトレキセートおよびその使用 |
| US12350271B2 (en) | 2018-02-14 | 2025-07-08 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| US20230000997A1 (en) * | 2019-08-06 | 2023-01-05 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CN112010862B (zh) * | 2020-10-23 | 2021-03-30 | 南京诺源医疗器械有限公司 | 一种主动靶向叶酸受体近红外荧光分子及其制备方法 |
| WO2023180103A1 (en) * | 2022-03-21 | 2023-09-28 | Immundiagnostik Ag | Kit of parts and microbiological method for assessment of the folate status in serum and red blood cells |
| CN115626928B (zh) * | 2022-10-13 | 2023-11-17 | 南京诺源医疗器械有限公司 | 一种靶向α型叶酸受体的培美近红外荧光分子作为荧光示踪剂的用途 |
| JP2024060824A (ja) * | 2022-10-20 | 2024-05-07 | プレミアアンチエイジング株式会社 | 経口製剤及びその製造方法 |
| WO2026018920A1 (ja) * | 2024-07-18 | 2026-01-22 | 国立大学法人九州大学 | 凍結乾燥装置、および、凍結乾燥試料とその製造方法 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2564319A1 (fr) | 1984-05-21 | 1985-11-22 | Inst Nat Sante Rech Med | Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees |
| US4584375A (en) * | 1984-08-21 | 1986-04-22 | Rensselaer Polytechnic Institute | Fluorine-containing antifolates incapable of polyglutamate formation |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| CA2057635A1 (en) | 1990-12-14 | 1992-06-15 | Hiroshi Akimoto | Condensed heterocyclic compounds, their production and use |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| WO1997027764A1 (en) | 1996-01-31 | 1997-08-07 | South Alabama Medical Science Foundation | Food and vitamin preparations containing the natural isomer of reduced folates |
| US20020168761A1 (en) | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US5912251A (en) | 1998-01-17 | 1999-06-15 | Nair; Madhavan G. | Metabolically inert anti-inflammatory and anti-tumor antifolates |
| US20050031679A1 (en) | 1998-03-27 | 2005-02-10 | Clemens Unger | Method for producing liposomal formulations of active ingredients |
| CN1239545C (zh) | 1998-07-09 | 2006-02-01 | 罗狄亚化学公司 | 水溶性或水可分散性接枝共聚物 |
| WO2001005405A1 (en) | 1999-07-16 | 2001-01-25 | The General Hospital Corporation | Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity |
| CN1095472C (zh) | 2000-04-17 | 2002-12-04 | 上海复康医药科技发展有限公司 | 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物 |
| EP1286661A2 (en) | 2000-06-09 | 2003-03-05 | OSI Pharmaceuticals, Inc. | Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| JP5102928B2 (ja) | 2000-06-30 | 2012-12-19 | イーライ リリー アンド カンパニー | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| AU2003211103A1 (en) | 2002-02-13 | 2003-09-04 | Northeastern University | Intracellular delivery of therapeutic agents |
| CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
| US7563590B2 (en) | 2002-08-30 | 2009-07-21 | Cypress Bioscience Inc. | Methods of quantifying methotrexate metabolites |
| US6921667B2 (en) * | 2003-03-07 | 2005-07-26 | Prometheus Laboratories, Inc. | Methods for direct detection of individual methotrexate metabolites |
| US20040265368A1 (en) | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| AU2005206163B2 (en) * | 2004-01-14 | 2011-06-30 | Gilead Sciences, Inc. | Lipid-based dispersions useful for drug delivery |
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| US7612071B2 (en) | 2004-03-12 | 2009-11-03 | Syntrix Biosystems, Inc. | Compositions and methods employing aminopterin |
| US20080260812A1 (en) | 2004-04-26 | 2008-10-23 | Takami Matsuyama C/O Kagoshima University | Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta) |
| LT3173073T (lt) | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| US7695908B2 (en) | 2004-06-15 | 2010-04-13 | Prometheus Laboratories Inc. | Methods for predicting methotrexate polyglutamate levels using pharmacogenetics |
| JP2008512490A (ja) | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス，インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
| JPWO2006035876A1 (ja) | 2004-09-29 | 2008-05-15 | 興和株式会社 | 関節リウマチの予防及び／又は治療薬 |
| US8126089B2 (en) | 2004-09-30 | 2012-02-28 | Alcatel Lucent | Method and apparatus for providing frame synchronization in a digital communication system that supports multiple modulation formats |
| US20100266709A1 (en) | 2004-12-16 | 2010-10-21 | Hicks Terry Lee | Compositions and Methods for Treating Burns |
| WO2006074416A1 (en) * | 2005-01-07 | 2006-07-13 | Health Research Inc. | 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| GB2424837B (en) | 2005-04-06 | 2010-10-06 | Cilag Ag Int | Injection device |
| AU2005335876A1 (en) | 2005-08-24 | 2007-03-01 | Protherics Medicines Development Limited | Cleavage of antifolate compounds |
| EP1962796A2 (en) | 2005-12-08 | 2008-09-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods for affecting liposome composition by ultrasound irradiation |
| WO2007098089A2 (en) * | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs |
| US9265746B2 (en) | 2006-05-31 | 2016-02-23 | Merck & Cie | Method for cell-specific targeting |
| WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| RU2423114C2 (ru) * | 2006-12-29 | 2011-07-10 | Тракон Фармасьютикалз, Инк. | Комбинации антифолатного агента в лечении рака |
| GB2453011B (en) * | 2006-12-29 | 2010-06-23 | Tracon Pharmaceuticals Inc | Antifolate agent compositions in the treatment of cancer |
| JP2010516694A (ja) | 2007-01-19 | 2010-05-20 | チェルシー・セラピューティクス，インコーポレイテッド | 新規な伝統的葉酸拮抗剤 |
| CN101977620B (zh) | 2008-03-18 | 2014-05-07 | 英国技术集团国际有限公司 | 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物 |
| GB0811360D0 (en) | 2008-06-20 | 2008-07-30 | Imp Innovations Ltd | Methods |
| EP2437596B1 (en) | 2009-06-03 | 2017-05-03 | Ex-Tek, LLC | Skin treatment compositions |
| TW201118098A (en) | 2009-08-13 | 2011-06-01 | Reddy S Lab Liimited Dr | Processes for preparing pemetrexed |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| CN102917690B (zh) | 2010-03-19 | 2016-08-24 | 麻省理工学院 | 脂质囊泡组合物和使用方法 |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| CA2800693A1 (en) | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Delivery of therapeutic agents to inflamed tissues using folate-targeted agents |
| WO2012033987A2 (en) | 2010-09-09 | 2012-03-15 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
| WO2012037068A1 (en) * | 2010-09-13 | 2012-03-22 | De Novo Diagnostics, Inc. | Methods for monitoring methotrexate therapy |
| WO2012061469A2 (en) | 2010-11-02 | 2012-05-10 | Sicor Inc. | Crystalline forms of pralatrexate |
| MX343607B (es) | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
| WO2012078708A1 (en) | 2010-12-07 | 2012-06-14 | Chelsea Therapeutics, Inc. | Combination comprising methotrexate and an antifolate compound |
| WO2012118806A2 (en) | 2011-02-28 | 2012-09-07 | The Regents Of The University Of California | Compositions and methods for detecting and treating cancer |
| WO2012121682A2 (en) | 2011-03-10 | 2012-09-13 | National Science And Technology Development Agency | Anti-folate antimalarials with dual-binding modes and their preparation |
| US8673914B2 (en) | 2011-03-28 | 2014-03-18 | St. John's University | Use of phosphodiesterase inhibitors for treating multidrug resistance |
| EP2508894A1 (en) | 2011-04-05 | 2012-10-10 | Receptomon LLC | Method for monitoring gene expression of translation and Integral/Secretory protein synthesis by magnetic resonance spectroscopy (MRS) |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| RS61235B1 (sr) | 2011-07-13 | 2021-01-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Lipozomi koji ko-inkapsuliraju bisfosfonat i amfipatički agens |
| SI2731972T1 (en) | 2011-07-15 | 2018-04-30 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| US20130122096A1 (en) | 2011-11-14 | 2013-05-16 | Silenseed Ltd. | Compositions for drug delivery and methods of manufacturing and using same |
| JPWO2014003137A1 (ja) | 2012-06-27 | 2016-06-02 | 旭化成メディカル株式会社 | 高アフィニティー抗体、及びその製造方法 |
| WO2014016740A2 (en) | 2012-07-23 | 2014-01-30 | Fresenius Kabi Oncology Ltd. | Improved process for the preparation of pralatrexate |
| WO2014046630A1 (en) | 2012-09-19 | 2014-03-27 | Keskin, Dilek | Tumor targeted liposomal drug delivery system |
| US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| US9207238B2 (en) | 2012-12-07 | 2015-12-08 | Kyowa Hakko Kirin Co., Ltd. | Anti-FOLR1 antibody |
| CN103040748B (zh) * | 2012-12-18 | 2014-07-02 | 海南圣欣医药科技有限公司 | 一种培美曲塞二钠脂质体注射剂 |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| SG11201509043RA (en) | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| MA40428A (fr) | 2014-08-14 | 2016-02-18 | L E A F Holdings Group Llc | Médicament à affinité encapsulé dans un liposome |
| CN104546723B (zh) * | 2015-02-11 | 2017-07-18 | 上海交通大学医学院附属新华医院 | 一种培美曲塞脂质体及其制备方法 |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| WO2017189961A1 (en) | 2016-04-29 | 2017-11-02 | Memorial Sloan Kettering Cancer Center | Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors |
| CN121177507A (zh) | 2016-08-12 | 2025-12-23 | L.E.A.F.控股集团公司 | α和γ-D聚谷氨酸化抗叶酸剂及其用途 |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| ES3062820T3 (en) | 2017-11-08 | 2026-04-14 | L E A F Holdings Group Llc | Platinum complexes and uses thereof |
| EP3749314A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES |
| WO2019157121A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| EP3749318A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| WO2019157145A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| CN111867593A (zh) | 2018-02-07 | 2020-10-30 | L.E.A.F.控股集团公司 | α聚谷氨酸化抗叶酸剂及其用途 |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| EP3749321A4 (en) | 2018-02-07 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated antifolates and uses thereof |
| JP7491572B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| US12350271B2 (en) | 2018-02-14 | 2025-07-08 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| JP7462950B2 (ja) | 2018-02-14 | 2024-04-08 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化メトトレキセートおよびその使用 |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| WO2019160735A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| KR102765012B1 (ko) | 2019-05-27 | 2025-02-07 | 삼성디스플레이 주식회사 | 표시 장치 |
| US20230000997A1 (en) | 2019-08-06 | 2023-01-05 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
-
2017
- 2017-08-12 CN CN202511400940.4A patent/CN121177507A/zh active Pending
- 2017-08-12 CN CN202511392165.2A patent/CN120939250A/zh active Pending
- 2017-08-12 KR KR1020237033296A patent/KR102708208B1/ko active Active
- 2017-08-12 CN CN201780062078.8A patent/CN109789212A/zh active Pending
- 2017-08-12 KR KR1020247030844A patent/KR20240141854A/ko active Pending
- 2017-08-12 CN CN201780052159.XA patent/CN109689104A/zh active Pending
- 2017-08-12 US US16/324,823 patent/US11344628B2/en active Active
- 2017-08-12 JP JP2019529465A patent/JP7576816B2/ja active Active
- 2017-08-12 AU AU2017308159A patent/AU2017308159B2/en active Active
- 2017-08-12 EP EP17840397.8A patent/EP3496757A4/en active Pending
- 2017-08-12 EP EP17840396.0A patent/EP3496756A4/en active Pending
- 2017-08-12 MX MX2019001755A patent/MX2019001755A/es unknown
- 2017-08-12 CA CA3033083A patent/CA3033083A1/en active Pending
- 2017-08-12 KR KR1020197005253A patent/KR102584446B1/ko active Active
- 2017-08-12 CA CA3177187A patent/CA3177187A1/en active Pending
- 2017-08-12 CA CA3033077A patent/CA3033077C/en active Active
- 2017-08-12 AU AU2017308158A patent/AU2017308158B2/en active Active
- 2017-08-12 KR KR1020247030845A patent/KR20240140191A/ko active Pending
- 2017-08-12 MX MX2019001756A patent/MX2019001756A/es unknown
- 2017-08-12 JP JP2019507107A patent/JP7227123B2/ja active Active
- 2017-08-12 KR KR1020197006810A patent/KR102585143B1/ko active Active
- 2017-08-12 EP EP22167260.3A patent/EP4052729A1/en active Pending
- 2017-08-12 EA EA201990473A patent/EA201990473A1/ru unknown
- 2017-08-12 KR KR1020237032981A patent/KR102708209B1/ko active Active
-
2019
- 2019-02-11 MX MX2023007496A patent/MX2023007496A/es unknown
- 2019-02-11 MX MX2022009187A patent/MX2022009187A/es unknown
- 2019-02-11 MX MX2023007726A patent/MX2023007726A/es unknown
-
2021
- 2021-12-07 US US17/544,191 patent/US12178882B2/en active Active
- 2021-12-07 US US17/544,196 patent/US12178883B2/en active Active
- 2021-12-07 US US17/544,182 patent/US12201695B2/en active Active
-
2022
- 2022-06-22 JP JP2022100445A patent/JP7733390B2/ja active Active
- 2022-07-28 US US17/875,724 patent/US11701432B2/en active Active
-
2023
- 2023-02-09 JP JP2023018363A patent/JP7538268B2/ja active Active
- 2023-05-24 US US18/201,275 patent/US20230381338A1/en not_active Abandoned
- 2023-11-07 AU AU2023263442A patent/AU2023263442B2/en active Active
- 2023-11-07 AU AU2023263441A patent/AU2023263441B2/en active Active
-
2024
- 2024-07-31 US US18/790,916 patent/US20240390514A1/en active Pending
- 2024-08-08 JP JP2024131755A patent/JP2024160315A/ja active Pending
- 2024-09-27 US US18/899,598 patent/US20250127920A1/en active Pending
- 2024-09-30 US US18/902,040 patent/US20250018055A1/en active Pending
- 2024-12-10 US US18/975,339 patent/US20250099608A1/en not_active Abandoned
-
2025
- 2025-01-06 JP JP2025001190A patent/JP2025072362A/ja active Pending
- 2025-03-04 US US19/069,794 patent/US20250195686A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524802A5 (enExample) | ||
| JP2019524885A5 (enExample) | ||
| JP2017526744A5 (enExample) | ||
| US20220211878A1 (en) | Cross-linked polymer modified nanoparticles | |
| JP7355394B2 (ja) | カロテノイド組成物およびその使用 | |
| JP2021512895A5 (enExample) | ||
| DK2714017T3 (en) | MEMBRANE-WRAPPED NANOPARTICLES AND METHOD OF USE | |
| JP2021513528A5 (enExample) | ||
| JP2021513525A5 (enExample) | ||
| JP2021514357A5 (enExample) | ||
| JP2021513550A5 (enExample) | ||
| JP2021513529A5 (enExample) | ||
| JP2021513531A5 (enExample) | ||
| AU2014218717A1 (en) | Targeted buccal delivery comprising cisplatin-loaded chitosan nanoparticles | |
| JP6321305B2 (ja) | 薬物送達用ナノ粒子組成物 | |
| Patil-Sen et al. | Nanotechnology: The Future for Cancer Treatment | |
| Thamphiwatana | Antimicrobial Nanotherapeutics Against Helicobacter pylori Infection | |
| EA047345B1 (ru) | Композиция каротиноида и способ ее получения | |
| HK1259723A1 (en) | Echinomycin formulation, method of making and method of use thereof | |
| HK1243002B (en) | Membrane encapsulated nanoparticles and method of use | |
| HK1197016B (en) | Membrane encapsulated nanoparticles and method of use |